TIL Desk/Business/New Delhi/ Healthcare major Zydus Cadila said on Friday its plasmid DNA vaccine candidate for COVID-19 (ZyCoV-D) developed indigenously at its vaccine technology centre has successfully completed the pre-clinical phase.
The company has received permission from the Drug Controller General of India — the Central Drugs Standard Control Organisation (CDSCO) — to initiate phase one and two human clinical trials in India.
In animal studies, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to completely neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate.
Related Posts
